COMPASS Pathways PlcNASDAQ: CMPS

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

· Issued by COMPASS Pathways Plc

Summary by 6ix AI

Compass Pathways reported third quarter 2026 results and business updates. It said its final New Drug Application, the filing asking the US Food and Drug Administration (FDA) to approve COMP360 for treatment-resistant depression (TRD), was nearing completion as of November 3, 2026.

Key details

  • The company said it expects to file the application within two weeks of its November 3, 2026 update.
  • Compass Pathways says its launch preparations are on track for an expected launch in the first half of 2027, subject to FDA approval.
  • The company says data from two Phase 3 (late-stage) trials it describes as positive show COMP360 has a rapid onset and a lasting effect.
  • Compass Pathways says 52-week open-label data (patients and doctors knew the treatment given) from its COMP005 trial showed added benefit from an extra COMP360 25 mg dose, extending how long the effect lasted out to one year.
  • The company estimates that 4 million people in the U.S. live with TRD.

What’s still pending

  • The New Drug Application had not yet been filed as of November 3, 2026.
  • Launch of COMP360 is subject to FDA approval; the company expects launch in the first half of 2027.

6ix AI wrote this summary from the release below and checked it against the release.

  • Final NDA submission nearing completion and will be filed in the next two weeks
  • Launch readiness on track for expected launch in H12027, subject to FDA approval
  • Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year
  • The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year
  • COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured

COMPASS Pathways Plc on 6ix

In the deck

Earlier from COMPASS Pathways

Later from COMPASS Pathways

All COMPASS Pathways news releases